ArticleBlood cancer journal2026

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study.

Zefeng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.